Danese S, Panaccione R, Abreu MT, Rubin DT, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. J Crohns Colitis 2023 Aug 31:jjad146. doi: 10.1093.
PMID: 37651686